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ATP-binding cassette (ABC) transporters prevent the access of pharmacological
compounds to the ischemic brain, thereby impeding the efficacy of stroke therapies.
ABC transporters can be deactivated by selective inhibitors, which potently increase
the brain accumulation of drugs. Concerns have been raised that long-term ABC
transporter deactivation may promote neuronal degeneration and, under conditions of
ischemic stroke, compromise neurological recovery. To elucidate this issue, we exposed
male C57BL/6 mice to transient intraluminal middle cerebral artery occlusion (MCAO)
and examined the effects of the selective ABCB1 inhibitor tariquidar (8 mg/kg/day)
or ABCC1 inhibitor MK-571 (10 mg/kg/day), which were administered alone or in
combination with each other over up to 28 days, on neurological recovery and brain
injury. Mice were sacrificed after 14, 28, or 56 days. The Clark score, RotaRod,
tight rope, and open field tests revealed reproducible motor-coordination deficits in
mice exposed to intraluminal MCAO, which were not influenced by ABCB1, ABCC1,
or combined ABCB1 and ABCC1 deactivation. Brain volume, striatum volume, and
corpus callosum thickness were not altered by ABCB1, ABCC1 or ABCB1, and
ABCC1 inhibitors. Similarly, neuronal survival and reactive astrogliosis, evaluated by
NeuN and GFAP immunohistochemistry in the ischemic striatum, were unchanged. Iba1
immunohistochemistry revealed no changes of the overall density of activated microglia
in the ischemic striatum of ABC transporter inhibitor treated mice, but subtle changes of
microglial morphology, that is, reduced microglial cell volume by ABCB1 deactivation
after 14 and 28 days and reduced microglial ramification by ABCB1, ABCC1 and
combined ABCB1 and ABCC1 deactivation after 56 days. Endogenous neurogenesis,
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assessed by BrdU incorporation analysis, was not influenced by ABCB1, ABCC1 or
combined ABCB1 and ABCC1 deactivation. Taken together, this study could not detect
any exacerbation of neurological deficits or brain injury after long-term ABC transporter
deactivation in this preclinical stroke model.
Keywords: focal cerebral ischemia, microglial morphology, mouse, multidrug resistance transporter,
neurodegeneration, neurogenesis, neurological recovery, P-glycoprotein
INTRODUCTION
Despite considerable progress in acute stroke treatment, i.e.,
intravenous thrombolysis and mechanical thrombectomy, stroke
remains the leading cause of long-term disability. Major efforts
have been made establishing pharmacological neuroprotection
therapies, largely without success. A major obstacle for
pharmacological compounds is the blood-brain barrier, which
actively prevents drug brain entry. The blood-brain barrier
contains ATP-binding cassette (ABC) transporters, which bind
lipophilic xenobiotics with high affinity, among which are many
brain-penetrating drugs (Soontornmalai et al., 2006; Hermann
and Bassetti, 2007). Upon ischemia, ABC transporters exhibit
coordinated expression changes on brain endothelial cells that
impede drug brain accumulation. Thus, the ABC transporter
ABCB1, which is preferentially expressed on the luminal
endothelial membrane and carries drugs in direction from the
brain to blood, is upregulated (Spudich et al., 2006), whereas
ABCC1, which is preferentially expressed on the abluminal
endothelial membrane and carries drugs in the opposite direction
from the blood to brain, is downregulated after intraluminal
middle cerebral artery occlusion (MCAO) (Kilic et al., 2008).
This coordinated regulation was shown to persist over up to
24 h post-MCAO and then returned to basal levels (Spudich
et al., 2006; Kilic et al., 2008). We previously showed that
the presence and absence of ABC transporters influences drug
concentrations in the ischemic brain by up to an order of
magnitude or even more, thus modifying neuroprotective drug
efficacy (Spudich et al., 2006; Kilic et al., 2008; ElAli and
Hermann, 2010). In view of the strong impact of ABC transporter
blockers, the pharmaceutical industry has developed clinically
applicable inhibitors, which have been used in phase 2 and 3
trials (Robey et al., 2018). In models of Alzheimer’s disease,
concerns have been raised that the long-term inhibition of
ABCB1 and ABCC1 may exacerbate neurodegeneration as a
consequence of reduced β-amyloid clearance (Cirrito et al.,
2005; Krohn et al., 2011). In focal cerebral ischemia, we did
not notice any aggravation of brain injury following ABCB1 or
ABCC1 deactivation in the acute stroke phase, i.e., during the
first 72 h post-MCAO (Spudich et al., 2006; Kilic et al., 2008).
This observation did not rule out the exacerbation of brain
injury in the subsequent post-acute phase, where major efforts
are currently made establishing neurorestorative treatments. To
explore possible injury-promoting effects, we herein studied
consequences of a long-term delivery of the ABCB1 and ABCC1
inhibitors tariquidar and MK-571 on post-ischemic neurological
deficits, delayed neurodegeneration and brain tissue remodeling
in mice exposed to intraluminal MCAO.
MATERIALS AND METHODS
Legal Requirements and Animal Housing
Experiments were conducted with government approval
(G1585/16) according to EU guidelines (Directive 2010/63/EU)
for the care and use of laboratory animals. Animals were housed
in groups in a 12 h:12 h light/dark cycle.
Statistical Planning, Blinding, and
Randomization
Statistical planning for the neurological examinations assumed
an alpha error of 5% and beta error (1–statistical power) of 20%,
for which 18 animals/group were required (Wang et al., 2018).
Experimenters were blinded by a third person providing drugs
with dummy names. Animal randomization was done by using
an open access R code.
Experimental Procedures and
Neurological Tests
Male C57BL/6 mice (23–27 g, Harlan, Horst, Netherlands)
were exposed to 30 min left-sided intraluminal MCAO during
1.5% isoflurane anesthesia (30% O2, remainder N2O) (Wang
et al., 2018). We decided to use a model of comparably mild
focal cerebral ischemia associated with moderate neurological
deficits, since we hypothesized that ABC transporter deactivation
would increase neurological deficits. Hence, a model was
required, in which an augmentation of deficits could reliably
be detected. Rectal temperature was kept at 37.0◦C using a
feedback-controlled heating system. Laser Doppler flow (LDF)
was monitored by a flexible probe above the core of the middle
cerebral artery territory. Immediately after reperfusion, animals
were intraperitoneally treated for 4 weeks with vehicle (0.9%
NaCl containing 4% DMSO), tariquidar (8 mg/kg/d; Sigma,
Deisenhofen, Germany), MK-571 (10 mg/kg/d; Enzo, Lörrach,
Germany), or tariquidar (8 mg/kg/d) plus MK-571 (10 mg/kg),
as described before (Spudich et al., 2006; Kilic et al., 2008).
Neurological deficits were evaluated weekly in the animals’
dark cycle using Clark’s neurological score (Clark et al., 1997),
RotaRod, tight rope and open field tests (Bacigaluppi et al., 2009;
Wang et al., 2018). Animals were sacrificed 14 (8 animals/group),
28 (8 animals/group) or 56 (18 animals/group) days post-MCAO
by transcardiac perfusion with ice-cold 0.9% NaCl followed by
4% paraformaldehyde in 0.9% NaCl. In animals sacrificed at
14 days post-MCAO, bromodeoxyuridine (BrdU; 50 mg/kg) was
intraperitoneally (i.p.) delivered daily at 7–13 days (Wang et al.,
2018). In case of animal dropouts, missing animals were replaced
by new animals. Dropout rates were 10 out of 44 animals operated
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(22.7%) in the vehicle group, 15 out of 49 animals (30.6%) in
the tariquidar group, 15 out of 50 animals (30.0%) in the MK-
571 group and 6 out of 41 animals (14.6%) in the tariquidar plus
MK-571 group, respectively.
Sham-operated mice were prepared by exposing mice to
1.5% isoflurane anesthesia (30% O2, remainder N2O). A midline
neck incision was made, and the left-sided carotid arteries were
isolated but left intact. These animals received intraperitoneal
vehicle injections as specified above, and were sacrificed after
14 days. In sham-operated mice, no animal dropouts were noted.
Brains were cut into 20 µm coronal cryostat sections.
Volumetry/Planimetry
Brain sections collected at millimeter intervals across the brain
were stained with cresyl violet. Brain tissue was outlined. Brain
volume, striatal volume, and corpus callosum thickness were
determined as described (Wang et al., 2018).
Conventional Immunohistochemistry
Sections obtained from the bregma level, i.e., the core of the
middle cerebral artery territory, were stained with chicken
anti-neuronal nuclei (NeuN) (1:300; ABN91 Merck-Millipore,
Darmstadt, Germany), rabbit anti-ionized calcium-binding
adaptor protein (Iba)-1 (1:300; 019-19741; Wako-Chemicals,
Neuss, Germany) and rat anti-glial fibrillary acidic protein
(GFAP) (1:300; 13-0300; Thermo Fisher Scientific, Waltham,
MA, United States) antibodies. Primary antibodies were detected
by secondary Alexa Fluor-488, Alexa Fluor-594, or Alexa Fluor-
647 labeled antibodies. Nuclei were counterstained with Hoechst-
33342 or 4′,6-diamidino-2-phenylindole (DAPI).
Confocal Microscopy and Conventional
Tissue Analysis
NeuN + neurons were evaluated using a Zeiss AxioObserver.Z1
inverted epifluorescence microscope using a 20× objective. Iba1
and GFAP stainings were evaluated using an Axio ZoomV.16
Lens Plan-Neofluar microscope using a 1.4 × objective. Images
were pre-processed and analyzed by an open-source ImageJ
(National Institutes of Health, Bethesda, MD, United States)
script and the pixel classification was performed using the
interactive learning and segmentation toolkit Ilastik (University
of Heidelberg, Heidelberg, Germany). NeuN + neurons were
counted in regions of interest in the dorsolateral striatum
measuring 665.6 µm × 526.5 µm using a CellProfiler
(Massachusetts Institute of Technology, Cambridge, MA,
United States) pipeline (information on pipeline and threshold
correction available upon request). Using an open-source ImageJ
script (also available upon request), the area of tissue covered by
Iba1 + microglia and GFAP + astrocytes was measured. Two
brain sections were examined per animal, out of which mean
values were formed.
Morphological Analysis of Activated
Microglia
Sections stained with Iba1 antibody were also evaluated using
a Leica SP8 confocal microscope using a 63 × objective.
20-µm-thick Z-stacks were produced that were composed
of 1331.2 µm × 1331.2 µm images that were scanned
at 0.5 µm steps. Following preprocessing of images, which
was performed using a customized ImageJ script, a three-
dimensional morphological analysis of cells was performed using
the MATLAB (MathWorks, Natick, MA, United States) based
script 3DMorph (York et al., 2018).
BrdU Incorporation Analysis
In sections obtained from the bregma level, endogenous
neurogenesis was examined by immunolabeling with monoclonal
rat anti-BrdU (1:100; ab6326; Abcam, United Kingdom),
polyclonal goat anti-doublecortin (DCX; 1:100; sc-8066, Santa
Cruz, Germany) and chicken anti-NeuN (1:300; ABN91;
Merck-Millipore) antibodies that were detected by Alexa
Fluor-488, Alexa Fluor-594, and Alexa Fluor-647 antibodies,
respectively. Nuclei were counterstained with Hoechst-33342.
Sections were evaluated with a 20 × objective using an
inverted AxioObserver.Z1 epifluorescence microscope (Zeiss,
Jena, Germany) analyzing regions of interest containing
the subventricular zone and striatum, respectively, using an
open-source ImageJ script (information on threshold settings
available upon request).
Statistical Analysis
Laser Doppler flow recordings and neurological tests were
analyzed by 2-way repeated measurement analysis of variance
(ANOVA) followed by Tukey’s tests, histochemical data by
2-way (>2 time-points) and 1-way ANOVA (1 time-point)
followed by Tukey’s tests. LDF recordings and neurological
tests are presented as mean ± SD values, histochemical
data as median (mean) ± interquartile range box-blots with
minimum/maximum data as whiskers. Significance thresholds
were set at p< 0.05.
RESULTS
Effects of ABC Transporter Deactivation
on LDF and Neurological Deficits
Intraluminal MCAO resulted in a LDF decrease to ∼20% of
baseline, followed by the rapid LDF restitution after reperfusion
that was not influenced by ABCB1 deactivation with tariquidar,
ABCC1 deactivation with MK-571 or combined ABCB1 and
ABCC1 deactivation with tariquidar and MK-571 (F = 0.01;
p = 0.99) (Figure 1A). Reproducible motor-coordination deficits
were noted in neurological score, RotaRod and tight rope tests
(Figures 1B–D), which persisted across the observation phase
and were associated with mild spontaneous motor hypoactivity
in open field texts (Figures 1E,F). Motor-coordination deficits
in the neurological score (F = 1.35; p = 0.98), RotaRod
test (F = 0.14; p = 0.93) and tight rope test (F = 0.24;
p = 0.86) were not influenced by ABC transporter deactivation.
Partial reversal of spontaneous motor hypoactivity in open
field tests was noted at 14–28 days in mice treated with the
ABCB1 inhibitor tariquidar (Figure 1E). This effect did not
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FIGURE 1 | Long-term delivery of ABCB1 inhibitor tariquidar and ABCC1 inhibitor MK-571 does not compromise post-ischemic motor-coordination performance.
(A) LDF recordings above the middle cerebral artery territory, (B–D) motor-coordination deficits evaluated using the Clark neurological score, RotaRod and tight rope
tests, and (E,F) spontaneous locomotor activity, that is, speed and time in center, examined by open field tests in mice exposed to transient intraluminal MCAO.
Vehicle, tariquidar (8 mg/kg/day), MK-571 (10 mg/kg/day) or tariquidar (8 mg/kg/day) plus MK-571 (10 mg/kg/day) were intraperitoneally administered over 28 days
starting after reperfusion. No differences were noted between groups. Results are means ± SD values (n = 18 animals/group).
reach statistical significance (F = 1.85; p = 0.14). Anxiety,
evaluated by the time in the center in the open field test,
was not influenced by ABC transporter deactivation (F = 0.89;
p = 0.58) (Figure 1F). In order to evaluate consequences of
ABC transporter deactivation under conditions of a more severe
ischemia, we also performed a sensitivity analysis, in which
we administered the inhibitors as above to mice exposed to
60 min MCAO, followed by 14 days survival. As for 30 min
MCAO, LDF above the middle cerebral artery territory and
neurological deficits evaluated by the Clark score were not
altered by ABCB1, ABCC1 or combined ABCB1 and ABCC1
deactivation (Supplementary Figure S1).
Effects on Brain Atrophy
Brain injury mainly affected the ischemic striatum and most
lateral parietal cortex, as described before (Wang et al.,
2018). Following the acute stroke phase, in which numerous
injured neurons were found throughout the middle cerebral
artery territory (see Supplementary Figure S2), progressive
atrophy was noted in the ischemic striatum (Figure 2A),
but not cortex (not shown). Whole brain volume (F = 0.79;
p = 0.49), striatum volume (F = 0.16; p = 0.91) and
corpus callosum thickness (F = 0.33; p = 0.80) were not
affected by the ABCB1, ABCC1, or ABCB1 and ABCC1
inhibitors (Figures 2A–C). In a sensitivity analysis in mice
exposed to 60 min MCAO, brain volume, striatal volume, and
corpus callosum thickness after 14 days were also unchanged
(Supplementary Figure S2).
Effects on Density of Surviving Neurons,
Activated Microglial Cells and Reactive
Astrocytes
Neuronal loss was prominent in the ischemic striatum
(Supplementary Figure S3) and in the most lateral parietal
cortex. In the ischemic striatum, the density of NeuN+ surviving
neurons was not influenced by ABC transporter inhibitors
(F = 0.13; p = 0.93) (Figure 2D). Similarly, the density
of Iba1 + activated microglia (F = 0.32; p = 0.80) and
GFAP + reactive astrocytes (F = 0.63; p = 0.59) was not
altered (Figures 2E,F).
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FIGURE 2 | Long-term delivery of ABCB1 inhibitor tariquidar and ABCC1 inhibitor MK-571 does not influence delayed neurodegeneration and brain remodeling.
(A) Whole brain volume, (B) striatal volume, and (C) corpus callosum thickness, outlined on cresyl violet-stained brain sections, as well as density of
(D) NeuN + neurons, (E) Iba1 + microglial cells, and (F) GFAP + reactive astrocytes, analyzed by immunohistochemistry in the ischemic striatum. Vehicle, tariquidar
(8 mg/kg/day), MK-571 (10 mg/kg/day) or tariquidar (8 mg/kg/day) plus MK-571 (10 mg/kg/day) were intraperitoneally delivered over up to 28 days post-MCAO. In
(A–C), sham-operated animals are also shown. In (D–F), regions of interest in the dorsolateral striatum measuring 665.6 µm × 526.5 µm were evaluated.
Representative microphotographs for animals sacrificed at 56 days after MCAO are shown. No differences were found between groups. Results are box-plots
representing medians (lines inside boxes)/means (crosses inside boxes) ± interquartile ranges with minimum/maximum data as whiskers (n = 8 animals/group).
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FIGURE 3 | ABCB1 inhibitor tariquidar and ABCC1 inhibitor MK571 induce modest microglial morphological changes. (A) Cell volume, (B) ramification index, and
(C) average branch length of microglial cells analyzed by Iba1 immunohistochemistry. Vehicle, tariquidar (8 mg/kg/day), MK-571 (10 mg/kg/day) or tariquidar
(8 mg/kg/day) plus MK-571 (10 mg/kg/day) were intraperitoneally delivered over up to 28 days post-MCAO. (D) Regions of interests measuring
1331.20 µm × 1331.20 µm were evaluated in the dorsolateral striatum. Z-stacks were generated from images acquired at 0.5 µm steps. (E) In these Z-stacks
individual cells were identified, reconstructed and analyzed. Representative cells for vehicle treated mice at all three time-points are shown. Results are box-plots
representing medians (lines inside boxes)/means (crosses inside boxes) ± interquartile ranges with minimum/maximum data as whiskers (n = 60–80 cells/group).
∗p < 0.05/∗∗p < 0.01 compared with vehicle.
Effects on Microglial Morphology
We next asked if ABC transporter deactivation might induce
more mild changes of microglial morphology. In a three-
dimensional analysis using the MATLAB-based script 3DMorph
(York et al., 2018), microglial cell volume in the ischemic
striatum was reduced by the ABCB1 inhibitor tariquidar after
14 and 28 days (that is, during drug delivery) (Figure 3A).
Microglial ramification, on the other hand, was reduced by the
ABCB1 inhibitor tariquidar and ABCC1 inhibitor MK-571 after
56 days (that is, after termination of drug delivery) (Figure 3B).
Average microglial branch length was not influenced (Figure 3C).
Our data indicate a modest microglial hyporesponsiveness
during ABCB1 inhibitor treatment, and a subtle microglial
overactivation after termination of ABCB1 and ABCC1 inhibitor
treatments. The appearance of Z-stacks and a schematic
reconstruction of representative microglial cells is shown in
Figures 3D,E.
Effects on Endogenous Neurogenesis
Endogenous neurogenesis has previously been shown to be
reduced in the subgranular zone of the dentate gyrus in otherwise
healthy Abcb1−/−, but not Abcc1−/− mice (Schumacher et al.,
2012). As reduced neurogenesis may compromise neurological
recovery (Doeppner et al., 2012), we finally evaluated whether
endogenous neurogenesis was decreased in the ischemic brain of
mice receiving ABC transporter inhibitors. The proliferation of
endogenous neural precursor cells (NPCs) in the subventricular
zone, evaluated by BrdU incorporation analysis (F = 0.07;
p = 0.97), and the neuronal differentiation of NPCs in
the subventricular zone, examined by BrdU incorporation
analysis combined with DCX and NeuN immunohistochemistry
(F = 0.03; p = 0.99 and F = 0.68; p = 0.57, respectively), was
not influenced by ABCB1, ABCC1, or ABCB1 and ABCC1
deactivation (Figures 4A–C). Likewise, the proliferation and
neuronal differentiation of endogenous NPCs in the ischemic
striatum was unchanged (F = 0.18; p = 0.90; F = 1.78; p = 0.18
and F = 0.66; p = 0.58, respectively) (Figures 4D–F).
DISCUSSION
Using an intraluminal MCAO model, in which we previously
characterized effects of the ABCB1 (Spudich et al., 2006) and
ABCC1 (Kilic et al., 2008) inhibitors tariquidar and MK-
571 on ischemic injury and the survival-promoting effects
of neuroprotective drugs that are known ABC transporter
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FIGURE 4 | ABCB1 inhibitor tariquidar and ABCC1 inhibitor MK-571 does not influence post-ischemic endogenous neurogenesis. (A,D) Cell proliferation, evaluated
by BrdU incorporation analysis, and (B,C,E,F) neurogenesis, examined by BrdU/doublecortin (DCX) and BrdU/NeuN double labeling, in mice exposed to transient
MCAO in the ipsilesional subventricular zone (A–C) and ischemic striatum (D–F). Vehicle, tariquidar (8 mg/kg/day), MK-571 (10 mg/kg/day) or tariquidar
(8 mg/kg/day) plus MK-571 (10 mg/kg/day) were intraperitoneally delivered. BrdU was applied at 7–13 days post-MCAO, followed by animal sacrifice at 14 days. No
differences were detected between groups. Results are box-plots representing medians (lines inside boxes)/means (crosses inside boxes) ± interquartile ranges with
minimum/maximum data as whiskers (n = 8 animals/group).
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substrates, we herein show that long-term ABCB1 and ABCC1
deactivation by the same inhibitors does not compromise
neurological performance and delayed neurodegeneration. Only
subtle changes of microglial morphology were noted in the brains
of ABCB1 and ABCC1 inhibitor treated mice, whereas the overall
density of Iba1 + activated microglial cells was unchanged.
Astroglial scar formation and endogenous neurogenesis were not
influenced by ABCB1 and ABCC1 deactivation. Already in our
previous studies, we did not see any evidence for exacerbated
ischemic brain injury (Spudich et al., 2006; Kilic et al., 2008).
These earlier observations were confined to the first 72 h post-
stroke. In the present study, we expanded these findings to
the post-acute stroke phase. Tariquidar is a highly selective
ABCB1 inhibitor that does not deactivate ABCC1, while MK-
571 inhibits ABCC1 but not ABCB1 (Spudich et al., 2006;
Kilic et al., 2008). Tariquidar has already been used in cancer
trials as add-on treatment for chemotherapeutics (Binkhathlan
and Lavasanifar, 2013). ABC transporter inhibitors, including
ABCB1 and ABCC1 inhibitors, have already been studied in
brain tumors in clinical trials (Binkhathlan and Lavasanifar,
2013). In animal models of Alzheimer’s disease, the long-term
deficiency of ABCB1 and ABCC1 has previously been found
to accelerate neurodegeneration as a consequence of reduced
β-amyloid elimination (Cirrito et al., 2005; Krohn et al., 2011).
Both ABCB1 and ABCC1 contribute to β-amyloid clearance
across the blood-brain barrier.
In this study, we decided to expose young, otherwise healthy
mice to focal cerebral ischemia, since we aimed to clarify
how ABC transporter deactivation affects neurological recovery
and brain injury independent of an associated Alzheimer’s
pathology. Besides β-amyloid, ABC transporters eliminate a
large number of endogenous substrates from the brain, such
as glutathione, sphingolipids, nucleosides, nucleotides, cyclic
nucleotides (e.g., cGMP), and glutathionized, glucuronidated
and sulfated organic anions (Hermann and Bassetti, 2007),
many of which have profound effects on neuronal survival
and brain remodeling. We were surprised to see that ABCB1
and ABCC1 deactivation did not affect neurological recovery
and secondary neurodegeneration. In our study, mild changes
of microglial morphology were noted in the brains of ABC
transporter inhibitor treated mice, that is, reduced microglial
cell volume after 14 and 28 days (that is, during drug
delivery) in mice receiving the ABCB1 inhibitor, which indicated
modest microglial hyporesponsiveness, and reduced microglial
ramification after 56 days (that is, after termination of drug
delivery) in mice receiving the ABCB1 and ABCB1 inhibitors,
which indicated subtle microglial hyperactivation. The total
number of Iba1 + activated microglia was not influenced by
ABCB1 or ABCC1 deactivation. In Abcb1−/− mice not exposed
to focal cerebral ischemia, increased microglial activation
associated with hyporamification of this microglia has previously
been demonstrated in the hippocampal CA3 region (Brzozowska
et al., 2017). In our study, ABCB1 and ABCC1 deactivation did
not influence reactive astrogliosis or endogenous neurogenesis.
In Abcb1−/− but not Abcc1−/− mice, reduced endogenous
neurogenesis revealed by DCX had previously been shown
(Schumacher et al., 2012).
Strengths of our study are the adequate statistical powering
and the use of a broad battery of neurological tests, which
we combined with rigid structural volumetry/planimetry and
immunohistochemical studies. Limitations are that we did not
study the additional impact of Alzheimer’s pathology on post-
ischemic neurological recovery and brain remodeling and,
perhaps, that we did not evaluate middle-aged or aged mice. The
brain abundance and function of ABC transporters decreases
with aging (e.g., Warrington et al., 2004; Zoufal et al., 2018).
We therefore did not expect an exacerbated neurodegeneration
after ABC transporter deactivation in aged mice. In view of the
failure of clinical trials using ABC transporter inhibitors mainly
in the cancer field, research interest in these drugs has meanwhile
waned (Robey et al., 2018). In view of this loss of interest,
very recent studies raised the question whether ABC transporter
inhibitors have prematurely been left in drug development
(Robey et al., 2018). The authors argued that at the time of the
discovery of existing drugs, the field lacked important knowledge
about the biology of ABC transporters, e.g., their overlap in
substrate binding, their species differences and their role in
human brain pathologies (Robey et al., 2018). The present study
could not detect any detrimental consequences of long-term ABC
transporter deactivation for neurological recovery or secondary
brain injury after focal cerebral ischemia. When considering
further studies in ischemic stroke, detrimental consequences
related to coexisting Alzheimer’s pathology should be examined.
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